financeliberal
Health Stocks: Opportunities Amid Uncertainty
Danaher, Eli Lilly, USATuesday, November 19, 2024
Despite these concerns, both companies have strong fundamentals. Danaher's bioprocessing business is growing, and its exposure to NIH funding is minimal. Eli Lilly's recent drop is mainly due to inventory destocking, not underlying demand issues. Both stocks could be bargains if the actual policy changes are less severe than feared.
Actions
flag content